Email this article 
PERAMPANEL IN THE TREATMENT OF REFRACTORY EPILEPSY IN EVERYDAY CLINICAL PRACTICE IN ADOLESCENTS
https://doi.org/10.17749/2077-8333.2016.8.4.084-090
Abstract
About the Authors
S. G. BurdRussian Federation
MD, Professor of the department of neurology, neurosurgery and medical genetics, the medical faculty,
ul. Ostrovityanova, 1, Moscow, 117997
M. B. Mironov
Russian Federation
PhD, Associate Prof. of the department of clinical physiology and functional diagnostics,
Volokolamskoe s., 91, Moscow 125371
M. M. Gunchenko
Russian Federation
deputy director of the outpatient work,
Michurinsky Prospect, 74, Moscow, 119602
M. N. Sarzhina
Russian Federation
head of the department of medical rehabilitation,
Michurinsky Prospect, 74, Moscow, 119602
References
1. Voronkova K.V., Petrukhin A.S., Pylaeva O.A., Kholin A.A. Rational antiepileptic pharmacotherapy [Ratsional’naya antiepilepticheskaya farmakoterapiya (in Russian)]. Moscow. 2008; 192 s.
2. Biró A., Stephani U., Tarallo T., Bast T., Schlachter K., Fleger M., Kurlemann G., Fiedler B., Leiz S., Nikanorova M., Wolff M., Müller A., Selch C., Staudt M., Kluger G. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015 Apr; 46 (2): 110-6. DOI: 10.1055/s-0035-1546276. Epub 2015 Mar 2.
3. Crépel V., Mulle C., Physiopathology of kainate receptors in epilepsy. Curr Opin Pharmacol. 2015 Feb; 20: 83-8. DOI: 10.1016/j.coph.2014.11.012. Epub 2014 Dec 13.
4. Ettinger A.B., LoPresti A., Yang H., Williams B., Zhou S., Fain R., Laurenza A. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015 Aug; 56 (8): 1252-63. DOI: 10.1111/epi.13054. Epub 2015 Jul 3.
5. Franco V., Crema F., Iudice A. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013; 70 (1): 35-40.
6. French J.A., Krauss G. L., Biton V. et al. Adjunctive perampanel for refractory partialonset seizures: randomized phase III study 304. Neurology. 2012; 79 (6): 589-96.
7. French J.A., Krauss G. L., Steinhoff B. J.et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013; 54 (1): 117-25.
8. Gidal B.E., Laurenza A., Hussein Z., Yang H., Fain R., Edelstein J., Kumar D., Ferry J. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015 May 12; 84 (19): 1972-80. DOI: 10.1212/WNL.0000000000001558. Epub 2015 Apr 15.
9. Kerling F., Kasper B.S. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl. 2013; (197): 25-9.
10. Kim H.D., Chi C.S., Desudchit T., Nikanorova M., Visudtibhan A., Nabangchang C., Chan D.W., Fong C.Y., Chang K.P., Kwan S.Y., Reyes F. L., Huang C.C., Likasitwattanakul S., Lee W. T., Yung A., Dash A. Review of clinical studies of perampanel in adolescent patients. Brain Behav. 2016 Jun 28; 6 (9): e00505.
11. Meador K. J., Yang H., Piña-Garza J.E., Laurenza A., Kumar D., Wesnes K.A. Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial. Epilepsia. 2016; 57 (2): 243-251. DOI: 10.1111/epi.13279.
12. Krauss G. L., Bar M., Biton V. et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012; 125 (1): 8-15.
13. Krauss G. L., Perucca E., Ben-Menachem E. et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia. 2014; 55 (7): 1058-68.
14. Lagae L., Villanueva V., Meador K. J., Bagul M., Laurenza A., Kumar D., Yang H. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016 Jul; 57 (7): 1120-9. DOI: 10.1111/epi.13417. Epub 2016 May 25.
15. De Liso P., Vigevano F., Specchio N., De Palma L., Bonanni P., Osanni E., Coppola G., Parisi P., Grosso S., Verrotti A., Spalice A., Nicita F., Zamponi N., Siliquini S., Giordano L., Martelli P., Guerrini R., Rosati A., Ilvento L., Belcastro V., Striano P., Vari M.S., Capovilla G., Beccaria F., Bruni O., Luchetti A., Gobbi G., Russo A., Pruna D., Tozzi A. E., Cusmai R. Effectiveness and tolerability of perampanel in children andadolescents with refractory epilepsies – An Italian observationalmulticenter study. Epilepsy Res. 2016 Nov; 127: 93-100. DOI: 10.1016/j.eplepsyres.2016.08.021. Epub 2016 Aug 18.
16. Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011 Mar; 11 (2): 56-63. DOI: 10.5698/1535-7511-11.2.56.
17. Rosenfeld W., Conry J., Lagae L., Rozentals G., Yang H., Fain R., Williams B., Kumar D., Zhu J., Laurenza A. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015 Jul; 19 (4): 435-45. DOI: 10.1016/j.ejpn.2015.02.008. Epub 2015 Mar 5.
18. Schmitz D., Mellor J., Nicoll R.A. Presynaptic kainate receptor mediation of frequency facilitation at hippocampal mossy fiber synapses. Science. 2001 Mar 9; 291 (5510): 1972-6. Epub 2001 Feb 8.
19. Steinhoff B. J., Ben-Menachem E., Ryvlin P., Shorvon S., Kramer L., Satlin A., Squillacote D., Yang H., Zhu J., Laurenza A. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013 Aug; 54 (8): 1481-9. DOI: 10.1111/epi.12212. Epub 2013 May 10.
20. Steinhoff B. J., O’Brien T.J., Yang H., Laurenza A., Patten A., Bibbiani F. Efficacy of adjunctive perampanel in adiopatic generalized epilepsy patients with drugresistant primary generalized tonic-clonic seizures by age, sex and race: double-blind placebo-controlled phase III trial. Poster presented at the 1st Congress of the European Academy of Neurology. Berlin. 20-23 June 2015.
21. Villanuevaa V., Garcésa M., LópezGonzálezb F.J., Rodriguez-Osoriob X., Toledoc M., Salas-Puigc J., GonzálezCuevasc M., Camposd D., Serratosae J.M., González-Giráldeze B., Maurif J.A., Camachof J. L., Sullerf A., Carre˜nog M., Gómezg J.B., Montoyah J., RodríguezUrangai J., Saiz-Diazj R., González-de la Alejaj J., Castillok A., López-Trigok J., Pozal J. J., Floresm J., Queroln R., Ojedao J., Ginerp P., Molinsq A., Estever P., Baigesra J. J. Safety, efficacy and outcomerelated factors of perampanel over 12months in a real-world setting: The FYDATA study. Epilepsy Research. 2016 (126): 201-210.
Supplementary files
For citation: Burd S.G., Mironov M.B., Gunchenko M.M., Sarzhina M.N. PERAMPANEL IN THE TREATMENT OF REFRACTORY EPILEPSY IN EVERYDAY CLINICAL PRACTICE IN ADOLESCENTS. Epilepsia and paroxyzmal conditions. 2016;8(4):84-90. https://doi.org/10.17749/2077-8333.2016.8.4.084-090
Refbacks
- There are currently no refbacks.